Concepts (155)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neurodevelopmental Disorders | 3 | 2021 | 460 | 1.180 |
Why?
|
| Neurological Rehabilitation | 1 | 2024 | 6 | 0.940 |
Why?
|
| Recovery of Function | 2 | 2017 | 691 | 0.790 |
Why?
|
| Craniocerebral Trauma | 3 | 2022 | 155 | 0.740 |
Why?
|
| Encephalitis | 2 | 2023 | 154 | 0.720 |
Why?
|
| Encephalitis, Herpes Simplex | 1 | 2019 | 10 | 0.670 |
Why?
|
| Child Abuse | 3 | 2022 | 208 | 0.670 |
Why?
|
| Glial Fibrillary Acidic Protein | 2 | 2019 | 173 | 0.660 |
Why?
|
| Meningoencephalitis | 1 | 2019 | 28 | 0.660 |
Why?
|
| Autoimmune Diseases of the Nervous System | 1 | 2019 | 34 | 0.650 |
Why?
|
| Hashimoto Disease | 1 | 2017 | 26 | 0.580 |
Why?
|
| Population Surveillance | 1 | 2021 | 650 | 0.570 |
Why?
|
| Autoantibodies | 2 | 2023 | 600 | 0.550 |
Why?
|
| Physical Therapy Modalities | 1 | 2017 | 93 | 0.540 |
Why?
|
| Nervous System Diseases | 1 | 2021 | 522 | 0.540 |
Why?
|
| Athletic Injuries | 1 | 2017 | 70 | 0.540 |
Why?
|
| Astrocytes | 1 | 2019 | 407 | 0.510 |
Why?
|
| Status Epilepticus | 1 | 2017 | 161 | 0.510 |
Why?
|
| Brain Concussion | 1 | 2017 | 225 | 0.460 |
Why?
|
| Brain Injuries | 2 | 2024 | 802 | 0.460 |
Why?
|
| Coronavirus Infections | 1 | 2021 | 633 | 0.450 |
Why?
|
| Patient Outcome Assessment | 1 | 2013 | 247 | 0.410 |
Why?
|
| Injury Severity Score | 3 | 2017 | 248 | 0.360 |
Why?
|
| Brain Diseases | 2 | 2023 | 417 | 0.330 |
Why?
|
| Child | 16 | 2024 | 30559 | 0.330 |
Why?
|
| Neurocognitive Disorders | 2 | 2018 | 77 | 0.290 |
Why?
|
| Critical Illness | 2 | 2024 | 743 | 0.290 |
Why?
|
| Fever | 2 | 2022 | 516 | 0.280 |
Why?
|
| Neuroimaging | 4 | 2022 | 404 | 0.230 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2022 | 7958 | 0.220 |
Why?
|
| Nerve Net | 2 | 2017 | 272 | 0.220 |
Why?
|
| Ascaridoidea | 1 | 2022 | 6 | 0.210 |
Why?
|
| Ascaridida Infections | 1 | 2022 | 6 | 0.210 |
Why?
|
| Epilepsy | 2 | 2022 | 984 | 0.210 |
Why?
|
| Diffuse Axonal Injury | 1 | 2022 | 10 | 0.210 |
Why?
|
| Spinal Injuries | 1 | 2022 | 37 | 0.200 |
Why?
|
| Meningitis | 1 | 2022 | 127 | 0.200 |
Why?
|
| Continuity of Patient Care | 1 | 2024 | 223 | 0.200 |
Why?
|
| Review Literature as Topic | 1 | 2021 | 83 | 0.190 |
Why?
|
| Language Development Disorders | 1 | 2022 | 166 | 0.190 |
Why?
|
| Nervous System | 1 | 2021 | 183 | 0.180 |
Why?
|
| Spinal Cord Ischemia | 1 | 2020 | 22 | 0.180 |
Why?
|
| White Matter | 1 | 2022 | 189 | 0.180 |
Why?
|
| Cartilage Diseases | 1 | 2020 | 20 | 0.180 |
Why?
|
| Encephalomyelitis, Acute Disseminated | 1 | 2020 | 13 | 0.180 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2022 | 181 | 0.180 |
Why?
|
| Embolism | 1 | 2020 | 66 | 0.170 |
Why?
|
| Hematoma, Subdural | 1 | 2019 | 30 | 0.170 |
Why?
|
| Infant | 7 | 2022 | 13970 | 0.170 |
Why?
|
| Patient Discharge | 2 | 2022 | 711 | 0.170 |
Why?
|
| ras GTPase-Activating Proteins | 1 | 2019 | 32 | 0.170 |
Why?
|
| Exanthema | 1 | 2022 | 210 | 0.170 |
Why?
|
| Humans | 26 | 2024 | 272091 | 0.160 |
Why?
|
| Botulism | 1 | 2018 | 10 | 0.160 |
Why?
|
| Brain Waves | 1 | 2019 | 51 | 0.160 |
Why?
|
| Autistic Disorder | 1 | 2022 | 350 | 0.160 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2022 | 266 | 0.160 |
Why?
|
| Lupus Vasculitis, Central Nervous System | 1 | 2018 | 17 | 0.160 |
Why?
|
| Adolescent | 8 | 2022 | 32730 | 0.160 |
Why?
|
| Child, Preschool | 6 | 2022 | 17056 | 0.150 |
Why?
|
| Leukopenia | 1 | 2018 | 153 | 0.150 |
Why?
|
| Cranial Nerve Diseases | 1 | 2018 | 77 | 0.150 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2022 | 477 | 0.150 |
Why?
|
| Critical Care | 1 | 2024 | 810 | 0.150 |
Why?
|
| Interdisciplinary Studies | 1 | 2017 | 6 | 0.140 |
Why?
|
| Child Development | 1 | 2019 | 268 | 0.140 |
Why?
|
| Post-Concussion Syndrome | 1 | 2017 | 54 | 0.140 |
Why?
|
| Rehabilitation Centers | 1 | 2017 | 73 | 0.140 |
Why?
|
| Brain | 3 | 2022 | 4260 | 0.130 |
Why?
|
| Cerebral Cortex | 1 | 2019 | 638 | 0.130 |
Why?
|
| Neural Pathways | 1 | 2017 | 314 | 0.130 |
Why?
|
| Male | 13 | 2023 | 129089 | 0.130 |
Why?
|
| Patient Readmission | 1 | 2020 | 592 | 0.120 |
Why?
|
| Time Factors | 2 | 2021 | 13139 | 0.120 |
Why?
|
| Telemedicine | 1 | 2022 | 549 | 0.120 |
Why?
|
| Disease Progression | 3 | 2022 | 6911 | 0.120 |
Why?
|
| Neutropenia | 1 | 2018 | 1001 | 0.110 |
Why?
|
| Language Development | 1 | 2013 | 29 | 0.110 |
Why?
|
| Stroke | 1 | 2022 | 1094 | 0.110 |
Why?
|
| Infant, Newborn | 3 | 2022 | 8612 | 0.100 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2017 | 359 | 0.100 |
Why?
|
| Neuropsychological Tests | 1 | 2017 | 1176 | 0.100 |
Why?
|
| Disability Evaluation | 1 | 2013 | 243 | 0.100 |
Why?
|
| Retinal Telangiectasis | 1 | 2012 | 4 | 0.100 |
Why?
|
| Alexander Disease | 1 | 2011 | 2 | 0.100 |
Why?
|
| Cerebellar Diseases | 1 | 2012 | 91 | 0.100 |
Why?
|
| Medulla Oblongata | 1 | 2011 | 47 | 0.100 |
Why?
|
| Telomere-Binding Proteins | 1 | 2012 | 89 | 0.100 |
Why?
|
| Walking | 1 | 2013 | 274 | 0.100 |
Why?
|
| Age Factors | 1 | 2021 | 5526 | 0.090 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 4900 | 0.090 |
Why?
|
| Retrospective Studies | 6 | 2023 | 39831 | 0.090 |
Why?
|
| Intellectual Disability | 1 | 2017 | 1064 | 0.090 |
Why?
|
| Female | 13 | 2023 | 149288 | 0.090 |
Why?
|
| Analysis of Variance | 1 | 2013 | 2337 | 0.080 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 4352 | 0.080 |
Why?
|
| Hospitals | 2 | 2022 | 493 | 0.080 |
Why?
|
| Telomere | 1 | 2012 | 547 | 0.080 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 5118 | 0.080 |
Why?
|
| Cerebellum | 1 | 2011 | 477 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2017 | 9500 | 0.070 |
Why?
|
| Length of Stay | 1 | 2013 | 2015 | 0.070 |
Why?
|
| Seizures | 2 | 2022 | 1051 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2022 | 15279 | 0.070 |
Why?
|
| Abnormalities, Multiple | 1 | 2012 | 1016 | 0.060 |
Why?
|
| DNA-Binding Proteins | 1 | 2017 | 5067 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2017 | 6885 | 0.060 |
Why?
|
| Hospitalization | 1 | 2013 | 2203 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2013 | 6236 | 0.060 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 1 | 2023 | 41 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 2058 | 0.050 |
Why?
|
| Oligodendroglia | 1 | 2023 | 112 | 0.050 |
Why?
|
| Amitriptyline | 1 | 2022 | 37 | 0.050 |
Why?
|
| KCNQ2 Potassium Channel | 1 | 2022 | 35 | 0.050 |
Why?
|
| Histiocytic Necrotizing Lymphadenitis | 1 | 2022 | 9 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2020 | 33909 | 0.050 |
Why?
|
| Pancytopenia | 1 | 2022 | 119 | 0.050 |
Why?
|
| Gain of Function Mutation | 1 | 2022 | 134 | 0.050 |
Why?
|
| Lymphadenopathy | 1 | 2022 | 94 | 0.050 |
Why?
|
| Paresthesia | 1 | 2020 | 33 | 0.040 |
Why?
|
| Intervertebral Disc Degeneration | 1 | 2020 | 22 | 0.040 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2022 | 194 | 0.040 |
Why?
|
| Syndrome | 1 | 2023 | 1407 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2022 | 274 | 0.040 |
Why?
|
| Muscle Weakness | 1 | 2020 | 114 | 0.040 |
Why?
|
| Cervical Vertebrae | 1 | 2020 | 220 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 5756 | 0.040 |
Why?
|
| Mandibulofacial Dysostosis | 1 | 2017 | 21 | 0.040 |
Why?
|
| Peripheral Nervous System | 1 | 2017 | 51 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 1116 | 0.040 |
Why?
|
| Aggression | 1 | 2019 | 253 | 0.040 |
Why?
|
| Codon, Nonsense | 1 | 2017 | 160 | 0.040 |
Why?
|
| Limb Deformities, Congenital | 1 | 2017 | 116 | 0.040 |
Why?
|
| Executive Function | 1 | 2017 | 149 | 0.030 |
Why?
|
| Psychomotor Performance | 1 | 2017 | 239 | 0.030 |
Why?
|
| Central Nervous System | 1 | 2017 | 457 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2020 | 790 | 0.030 |
Why?
|
| Autism Spectrum Disorder | 1 | 2019 | 375 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2017 | 1855 | 0.020 |
Why?
|
| Muscle Hypotonia | 1 | 2012 | 183 | 0.020 |
Why?
|
| Phenotype | 1 | 2023 | 6517 | 0.020 |
Why?
|
| Texas | 1 | 2022 | 6440 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2017 | 2867 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 5935 | 0.020 |
Why?
|
| Aging | 1 | 2017 | 1578 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 2357 | 0.020 |
Why?
|
| Biomarkers | 1 | 2019 | 5115 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2012 | 3078 | 0.020 |
Why?
|
| Base Sequence | 1 | 2012 | 5502 | 0.020 |
Why?
|
| United States | 1 | 2022 | 16066 | 0.010 |
Why?
|
| Histones | 1 | 2012 | 1514 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 6783 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2012 | 2576 | 0.010 |
Why?
|
| Animals | 1 | 2022 | 62827 | 0.010 |
Why?
|
| Mutation | 1 | 2011 | 15944 | 0.010 |
Why?
|